#1 Clinical Trials Search in Europe

Forimtamig

Forimtamig is an investigational drug currently being studied in clinical trials for patients with relapsed or refractory multiple myeloma (r/r MM). These trials aim to evaluate the safety, effectiveness, and optimal dosing of Forimtamig, both as a standalone treatment and in combination with other drugs. The studies involve patients who have limited treatment options or are intolerant to established therapies, offering hope for improved outcomes in this challenging condition.

Table of Contents

What is Forimtamig?

Forimtamig, also known by its research name RO7425781, is a new drug being studied for the treatment of multiple myeloma[1]. Multiple myeloma is a type of blood cancer that affects plasma cells, which are a type of white blood cell responsible for producing antibodies. This innovative medication is currently undergoing clinical trials to evaluate its safety and effectiveness in patients who have relapsed or become resistant to other treatments.

What Does Forimtamig Treat?

Forimtamig is specifically being developed to treat relapsed or refractory multiple myeloma (r/r MM)[1][2]. This means it’s intended for patients who have:

  • Already undergone treatment for multiple myeloma, but the cancer has returned (relapsed)
  • Not responded well to previous treatments or have become resistant to them (refractory)
The drug is being studied as a potential option for patients who have exhausted standard treatment options or cannot tolerate established therapies.

How is Forimtamig Administered?

Forimtamig can be administered in two ways[1]:

  • Intravenous (IV) infusion: The medication is delivered directly into the bloodstream through a vein.
  • Subcutaneous (SC) injection: The drug is injected just under the skin.
The specific dosing schedule and method of administration may vary depending on the phase of the clinical trial and the individual patient’s needs.

Clinical Trials

Forimtamig is currently being evaluated in two main clinical trials:

  1. Phase I Study (NCT04557150)[1]: This is a first-in-human study designed to assess the safety and pharmacokinetics (how the drug moves through the body) of Forimtamig. It consists of two parts:
    • Part 1: Dose Escalation – Researchers gradually increase the dose to determine the safest and most effective amount.
    • Part 2: Dose Expansion – The recommended dose from Part 1 is given to a larger group of patients to further evaluate its effects.
  2. Phase IB/II Study (NCT06055075)[2]: This study aims to evaluate Forimtamig alone and in combination with other drugs. It also has two phases:
    • Dose Exploration Phase: Different doses of Forimtamig are tested in combination with other drugs.
    • Dose Expansion Phase: The most promising dose and combination are given to a larger group of patients.
These trials help researchers understand how well the drug works and what side effects it may cause.

Combination Therapies

In addition to being studied as a standalone treatment, Forimtamig is being evaluated in combination with other multiple myeloma drugs[2]:

  • Carfilzomib: A proteasome inhibitor that helps kill cancer cells.
  • Daratumumab: A monoclonal antibody that targets specific proteins on myeloma cells.
These combinations are being tested to see if they can improve the effectiveness of treatment compared to using Forimtamig alone.

Safety and Side Effects

As with any new medication, understanding the safety profile and potential side effects of Forimtamig is crucial. The clinical trials are closely monitoring[1][2]:

  • Adverse Events (AEs): Any unfavorable and unintended sign, symptom, or disease associated with the use of the drug.
  • Dose Limiting Toxicities (DLTs): Side effects that are severe enough to prevent increasing the dose of the medication.
  • Anti-Drug Antibodies (ADAs): The body’s immune response to the drug, which could potentially reduce its effectiveness.
Patients participating in these trials are closely monitored for any side effects or safety concerns.

Effectiveness Measures

To determine how well Forimtamig works, researchers are looking at several key measures[1][2]:

  • Objective Response Rate (ORR): The percentage of patients whose cancer shrinks or disappears after treatment.
  • Duration of Response (DOR): How long the cancer remains controlled after treatment.
  • Progression-Free Survival (PFS): The length of time during and after treatment that a patient lives with the disease without it worsening.
  • Overall Survival (OS): How long patients survive after starting treatment.
  • Complete Response (CR) and Stringent Complete Response (sCR) Rates: The percentage of patients who show no signs of myeloma after treatment.
  • Very Good Partial Response (VGPR) Rate: The percentage of patients who have a significant reduction in myeloma proteins.
These measures help doctors and patients understand how effective Forimtamig is in treating relapsed or refractory multiple myeloma.

Aspect Details
Drug Name Forimtamig (RO7425781)
Condition Studied Relapsed or Refractory Multiple Myeloma (r/r MM)
Administration Methods Intravenous (IV) infusion, Subcutaneous (SC) injection
Study Phases Phase I, Phase IB/II
Study Designs Dose-escalation, Dose-expansion, Combination therapy
Combination Therapies Carfilzomib, Daratumumab
Primary Outcomes Safety (Adverse Events), Efficacy (Objective Response Rate)
Secondary Outcomes Duration of Response, Progression-Free Survival, Overall Survival, Pharmacokinetics
Study Duration Up to approximately 24 months

FAQ

  • What is Forimtamig? Forimtamig is an experimental drug being tested in clinical trials for patients with relapsed or refractory multiple myeloma. It is also known by its code name RO7425781.
  • How is Forimtamig administered? Forimtamig can be administered through intravenous (IV) infusion or subcutaneous (SC) injection, depending on the specific trial and dosing regimen.
  • What are the main goals of the Forimtamig clinical trials? The main goals are to evaluate the safety, tolerability, and effectiveness of Forimtamig in treating relapsed or refractory multiple myeloma. The trials also aim to determine the best dosing regimens and explore potential combinations with other drugs.
  • Are there any combination therapies being tested with Forimtamig? Yes, some trials are testing Forimtamig in combination with other drugs, such as carfilzomib and daratumumab, to potentially enhance its effectiveness in treating multiple myeloma.
  • What are some of the outcomes being measured in these trials? The trials are measuring various outcomes, including the percentage of patients experiencing side effects, objective response rate, duration of response, progression-free survival, and overall survival. They are also evaluating how the body processes the drug and if patients develop antibodies against it.

Ongoing Clinical Trials on Forimtamig

  • Study on the Safety and Effects of Forimtamig, Tocilizumab, and Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma

    Not recruiting

    1 1 1 1
    Investigated drugs:
    Denmark France Germany Italy Spain

Glossary

  • Multiple Myeloma: A type of blood cancer that affects plasma cells, which are a type of white blood cell found in bone marrow. In multiple myeloma, abnormal plasma cells multiply and can cause damage to bones, kidneys, and other organs.
  • Relapsed or Refractory Multiple Myeloma (r/r MM): A condition where multiple myeloma has returned after treatment (relapsed) or has not responded to treatment (refractory).
  • Intravenous (IV) infusion: A method of administering medication directly into a vein using a needle or catheter.
  • Subcutaneous (SC) injection: A method of administering medication by injecting it into the layer of tissue between the skin and muscle.
  • Dose-escalation: A process in clinical trials where the dose of a drug is gradually increased to determine the safest and most effective dose.
  • Recommended Phase 2 Dose (RP2D): The dose of a drug determined to be safe and potentially effective, based on initial studies, for use in further clinical trials.
  • Adverse Events (AEs): Any unfavorable or unintended sign, symptom, or disease that occurs during a clinical trial, which may or may not be related to the treatment being studied.
  • Dose Limiting Toxicities (DLTs): Side effects of a treatment that are severe enough to prevent an increase in dosage or require a reduction in dosage.
  • Objective Response Rate (ORR): The proportion of patients whose cancer shrinks or disappears after treatment.
  • Duration of Response (DOR): The length of time that a tumor continues to respond to treatment without growing or spreading.
  • Progression-Free Survival (PFS): The length of time during and after treatment that a patient lives with the disease without it worsening.
  • Overall Survival (OS): The length of time from the start of treatment that patients are still alive.
  • Anti-Drug Antibodies (ADAs): Proteins produced by the immune system that specifically target and potentially neutralize a therapeutic drug.
  • Pharmacokinetics: The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.
  • Bioavailability: The proportion of a drug that enters the circulation when introduced into the body and is able to have an active effect.

References

  1. https://clinicaltrials.gov/study/NCT04557150
  2. https://clinicaltrials.gov/study/NCT06055075